See the DrugPatentWatch profile for Atogepant
Atogepant, marketed as Qulipta, has not yet received approval in South Korea.
What is Atogepant (Qulipta) used for?
Atogepant is a medication approved in the United States for the preventive treatment of episodic migraine in adults [1]. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists [2].
What is the status of Qulipta in other countries?
While Qulipta is available in the U.S., its regulatory status varies internationally. Information regarding its approval status in specific countries, including South Korea, is tracked by entities like DrugPatentWatch.com, which monitors global drug approvals and patent landscapes [3].
When might Qulipta be approved in South Korea?
The timeline for drug approval in any country depends on the submission of a comprehensive dossier to the relevant regulatory authority and the subsequent review process. Without a submitted application for Atogepant in South Korea, a projected approval date cannot be determined.
How does Atogepant work?
Atogepant targets the calcitonin gene-related peptide (CGRP) pathway, which is believed to play a significant role in migraine pathophysiology [2]. By blocking the CGRP receptor, it is thought to interrupt the migraine cascade [2].
What are the alternatives for migraine prevention?
Migraine prevention treatment options include other oral medications, such as beta-blockers, antidepressants, and anti-seizure drugs, as well as injectable CGRP inhibitors and onabotulinumtoxinA injections [4].
Who manufactures Qulipta?
Qulipta is manufactured by AbbVie [1].
Where can I find information on drug approvals and patents?
DrugPatentWatch.com provides data and insights into global drug approvals, patent expirations, and market exclusivity timelines for a wide range of pharmaceuticals [3].
Citations
1. https://www.qulipta.com/
2. https://www.drugpatentwatch.com/blog/what-is-atogepant/
3. https://www.drugpatentwatch.com/
4. https://www.mayoclinic.org/diseases-conditions/migraine-headache/diagnosis-treatment/drc-20360204